Optic IconOptic Logo
|
SearchCollectionsBenchmarks
Product

Vehicle

Aliases
BBI-4000 Gel, 0%, Control, Placebo, Vehicle Cream (3 other aliases)

97 clinical trials

61 indications

Indication
Psoriasis
Indication
Dry Eye Syndrome
Indication
Acquired Ptosis
Indication
Inflammation
Indication
Diabetic Macular Edema
Indication
Dry Eye
Indication
Alopecia
Indication
Androgenetic
Indication
Sjögren's syndrome
Indication
Hyperhidrosis
Indication
Hand-Foot Skin Reaction
Indication
Atopic Dermatitis
Indication
Presbyopia
Indication
Pterygium
Indication
Myopia
Indication
Allergic Conjunctivitis
Indication
Acute Infectious Keratoconjunctivitis
Indication
Pruritus
Indication
Sexual Arousal Disorder
Indication
Crow's feet
Indication
Lymphocytic leukemia
Indication
Crow's Feet
Indication
Glabellar Frown Lines
Indication
Epidermolysis Bullosa Simplex
Indication
Netherton Syndrome
Indication
Lichen sclerosus
Indication
Hand Eczema
Indication
Acne Rosacea
Indication
Healthy
Indication
Non-segmental Vitiligo
Indication
Parkinson's disease
Indication
Genital Warts
Indication
Perianal Warts
Indication
Cataract
Indication
Chronic Hand Eczema
Indication
Allergic Rhinitis
Indication
Allergic Rhinitis Due to Grass Pollen
Indication
Healthy Control Participants
Indication
Osteoarthritis
Indication
Knee
Indication
Progressive
Indication
Traumatic Skin Lesions
Indication
Persistent Corneal Epithelial Defect
Indication
Stage 1 hypertension
Indication
Hypertension
Indication
Stage I
Indication
Vulvovaginal Atrophy
Indication
Neurotrophic Keratopathy
Indication
Migraine
Indication
Nail Fungus
Indication
Neurofibroma
Indication
Neurofibromatosis type 1
Indication
Vitiligo
Indication
Acne Vulgaris
Indication
Red Eye
Indication
Miosis
Indication
Eye Disorders
Indication
Xerosis Cutis
Indication
Photodamaged Skin
Indication
Postinflammatory Hyperpigmentation
Indication
Keloid
Clinical trial
1205
Status: Completed, Estimated PCD: 2015-01-01
Clinical trial
A Multicenter, Randomized, Double-masked and Placebo-controlled Study Evaluating the Efficacy and Safety of SI-614 Ophthalmic Solution in Patients With Dry Eye
Status: Completed, Estimated PCD: 2023-03-02
Clinical trial
A Phase 1/2a Study of LEV102 Topical Gel in Subjects With Acquired Blepharoptosis
Status: Completed, Estimated PCD: 2023-06-24
Clinical trial
A Phase 3 Double-masked, Randomized, Multicenter Study of the Efficacy and Safety of OCS 01 Eye Drops in Subjects With Diabetic Macular Edema
Status: Recruiting, Estimated PCD: 2025-12-01
Clinical trial
A Phase 2, Double-masked, Randomized, Vehicle-controlled Study of VVN461 Ophthalmic Solution in Treating Post -Operative Ocular Inflammation in Subjects Undergoing Routine Unilateral Cataract Surgery
Status: Recruiting, Estimated PCD: 2024-12-15
Clinical trial
A Phase 2a, Double-Masked, Randomized, Vehicle-controlled Trial Evaluating the Safety and Efficacy Activity of 1% and 5% VVN001 Compared to Vehicle in Subjects With Dry Eye Disease
Status: Completed, Estimated PCD: 2021-12-01
Clinical trial
A 6-month Phase 3, Multicenter, Prospective, Randomized, Double-Blind, Vehicle-Controlled Study, to Evaluate the Efficacy and Safety of Topically Applied Clascoterone Solution for the Treatment of Androgenetic Alopecia in Males, Followed by a 6-month Single-Blind Treatment With Clascoterone or Vehicle Solution
Status: Recruiting, Estimated PCD: 2024-06-01
Clinical trial
A Phase 3 Multi-Center, Randomized, Double Masked, Vehicle Controlled Study to Assess the Safety and Efficacy of ST-100 (Vezocolmitide) Ophthalmic Solution 60 μg/ml Ophthalmic Solution in Subjects Diagnosed With Dry Eye Disease (DED)
Status: Recruiting, Estimated PCD: 2024-06-30
Clinical trial
Tivanisiran for Dry Eye in Subjects With Sjögren's Syndrome
Status: Completed, Estimated PCD: 2023-12-11
Clinical trial
A First-in-Human, Phase 1/2, Dose-ascending, Multicenter, Masked, Randomized, Vehicle-controlled Study Evaluating the Safety, Tolerability, and Pharmacokinetics of AGN-241622 in Healthy Participants and Participants With Presbyopia (Stage 1 and Stage 2) and Efficacy in Participants With Presbyopia (Stage 2)
Status: Terminated, Estimated PCD: 2022-12-05
Clinical trial
A 6-month Phase 3, Multicenter, Prospective, Randomized, Double-Blind, Vehicle-Controlled Study, to Evaluate the Efficacy and Safety of Topically Applied Clascoterone Solution for the Treatment of Androgenetic Alopecia in Males, Followed by a 6-month Single-Blind Treatment With Clascoterone or Vehicle Solution
Status: Recruiting, Estimated PCD: 2024-08-01
Clinical trial
A Multicenter, Randomized, Double-Blinded, Vehicle-Controlled Study to Evaluate the Safety and Efficacy of Topically Applied Sofpironium Bromide Gel, 15% in Subjects With Axillary Hyperhidrosis
Status: Completed, Estimated PCD: 2021-06-25
Clinical trial
A Phase II Study to Evaluate the Safety and Efficacy of OQL011 on VEGFR Inhibitor-Associated Hand-Foot Skin Reaction in Cancer Patients
Status: Active (not recruiting), Estimated PCD: 2024-02-26
Clinical trial
A Phase 2b, Multicenter, Randomized, Double-Blind, Vehicle-Controlled, Parallel-Group Study to Determine the Safety, Tolerability, Pharmacokinetics, and Efficacy of ATI-1777 in Patients 12 to 65 Years Old With Mild to Severe Atopic Dermatitis (AD)
Status: Completed, Estimated PCD: 2023-10-26
Clinical trial
Multicenter, Double-Masked, Randomized, Vehicle-Controlled 12-Month Parallel Comparison of the Safety and Efficacy of 0.1% and 0.2% CBT-001 Versus Vehicle, Dosed Twice-Daily, in Patients With Pterygium
Status: Recruiting, Estimated PCD: 2025-12-31
Clinical trial
A Multicenter, Randomized, Double-masked, Vehicle-controlled Study to Assess the Safety and Efficacy of SYD-101 Ophthalmic Solution for the Treatment of Myopia in Children
Status: Active (not recruiting), Estimated PCD: 2024-06-01
Clinical trial
A Multi-Center, Double-Masked, Randomized, Vehicle and Active Controlled Evaluation of the Onset and Duration of Action of KetoNaph Ophthalmic Solution in the Conjunctival Allergen Challenge Model of Acute Allergic Conjunctivitis
Status: Completed, Estimated PCD: 2008-12-01
Clinical trial
Phase 2, Multicenter, Randomized, Double-Masked, Vehicle-Controlled Study of INV-102 Ophthalmic Solution in Patients With Acute Infectious Keratoconjunctivitis
Status: Recruiting, Estimated PCD: 2024-06-01
Clinical trial
Tivanisiran for Dry Eye in Subjects With Sjögren's Syndrome
Status: Completed, Estimated PCD: 2023-12-11
Clinical trial
A Two-part, Multicenter, Randomized, Double-blind Study to Evaluate the Efficacy and Safety of Oral Difelikefalin as Adjunct Therapy to a Topical Corticosteroid for Moderate-to-Severe Pruritus in Adult Subjects With Atopic Dermatitis
Status: Terminated, Estimated PCD: 2024-02-02
Clinical trial
Phase 1 Single-Dose Double-Blind Vehicle-Controlled 3-Way Crossover Study Using Thermography to Assess the Pharmacodynamics and Pharmacokinetics of L-Arginine and Sildenafil Contained in Sildenafil Cream 3.6% in Normal Healthy Premenopausal Women
Status: Recruiting, Estimated PCD: 2024-04-01
Clinical trial
A 4-Week, Phase II, Multicenter, Randomized, Double-Masked, Vehicle-Controlled, Parallel Group Study With 4 Weeks of Follow-Up to Evaluate Safety and Efficacy of a New Formulation of Recombinant Human Nerve Growth Factor (rhNGF) Eye Drop Solution at Two Different Concentrations in Patients With Dry Eye Disease
Status: Recruiting, Estimated PCD: 2024-09-01
Clinical trial
Clinical Trial to Evaluate ET-01 in Subjects With Lateral Canthal Lines
Status: Active (not recruiting), Estimated PCD: 2024-04-01
Clinical trial
A Phase 1/2 Study to Establish An Initial Therapeutic Range and Safety Data for AI-09 in the Treatment of Glabellar Lines
Status: Active (not recruiting), Estimated PCD: 2024-05-01
Clinical trial
A Multi-Center, Double-Masked, Vehicle-Controlled, Evaluation of the Efficacy and Safety of CSF-1 in the Temporary Correction of Presbyopia (the NEAR-2 Study: Near Eye-vision Acuity Restoration)
Status: Completed, Estimated PCD: 2022-01-21
Clinical trial
A Phase 3, Double-Blind, Randomized, Vehicle-Controlled, Efficacy and Safety Study of Ruxolitinib Cream Followed by a Long-Term Safety Extension Period in Children (Ages≥ 2 Years to < 12 Years) With Atopic Dermatitis ((TRuE-AD3)
Status: Completed, Estimated PCD: 2023-05-10
Clinical trial
An International, Multicenter, Randomized, Double-Blind, Parallel Group, Vehicle-Controlled, Phase 2/3 Study With Open-Label Extension Evaluating the Efficacy and Safety of Diacerein 1% Ointment for the Treatment of Generalized Epidermolysis Bullosa Simplex (EBS)
Status: Recruiting, Estimated PCD: 2025-08-01
Clinical trial
A PHASE 2B, RANDOMIZED, DOUBLE BLIND, VEHICLE CONTROLLED, PARALLEL GROUP STUDY TO ASSESS THE EFFICACY, SAFETY, TOLERABILITY AND PHARMACOKINETICS OF MULTIPLE DOSE LEVELS OF PF-07038124 OINTMENT FOR 12 WEEKS IN PARTICIPANTS 12 YEARS AND OLDER AND WITH MILD-TO-MODERATE ATOPIC DERMATITIS OR MILD-TO-SEVERE PLAQUE PSORIASIS
Status: Completed, Estimated PCD: 2023-07-31
Clinical trial
A Multicenter, Randomized, Vehicle-Controlled, Double-Blind, Parallel Comparison Study of QRX003 Lotion in Subjects With Netherton Syndrome
Status: Recruiting, Estimated PCD: 2025-01-31
Clinical trial
A Phase 2, Randomized, Double-Blind, Vehicle-Controlled, Study of the Efficacy and Safety of Ruxolitinib Cream in Participants With Lichen Sclerosus
Status: Completed, Estimated PCD: 2023-09-01
Clinical trial
A Multi-Center, Double-Masked, Vehicle-Controlled, Evaluation of the Efficacy and Safety of CSF-1 in the Temporary Correction of Presbyopia (the NEAR-1 Study: Near Eye-vision Acuity Restoration)
Status: Completed, Estimated PCD: 2022-02-11
Clinical trial
A Phase 2, Double-Blind, Randomized, 16-Week, Vehicle-Controlled, Efficacy and Safety Study of Ruxolitinib Cream Followed by an Open-Label Extension Period in Adults With Chronic Hand Eczema
Status: Active (not recruiting), Estimated PCD: 2024-08-26
Clinical trial
Phase 1/2, Multicenter, Randomized, Double-Masked, Vehicle-Controlled, Multiple Ascending Dose (Part 1) and Optional Dose Expansion (Part 2) Study of INV-102 Ophthalmic Solution in Adult Subjects With Moderate Symptomatic Dry Eye Disease
Status: Completed, Estimated PCD: 2023-05-02
Clinical trial
A Phase 3 Study Evaluating the Safety and Efficacy of AR-15512, a Cold Thermoreceptor Modulator, for the Treatment of Dry Eye Disease (COMET-3)
Status: Completed, Estimated PCD: 2023-10-17
Clinical trial
A Multicenter, Randomized, Double-Blinded, Vehicle-Controlled Study to Evaluate the Safety and Efficacy of Topically Applied Sofpironium Bromide Gel, 15% in Subjects With Axillary Hyperhidrosis
Status: Completed, Estimated PCD: 2021-08-13
Clinical trial
A Vehicle-Controlled, Double-Blind, Randomized Phase II Study of B244 Delivered as a Topical Spray to Determine Safety and Efficacy in Subjects With Mild to Moderate Rosacea
Status: Completed, Estimated PCD: 2019-02-11
Clinical trial
A Phase 1, Randomized, Double-blinded, Vehicle-controlled, Single and Multi-Dose, Dose Escalation Study to Evaluate the Safety, Tolerability, and Pharmacokinetics in Healthy Volunteers of the Novel Self-Administered Intranasal CG- SpikeDown Antiviral Drug
Status: , Estimated PCD: 2023-01-01
Clinical trial
Topical Ruxolitinib Evaluation in Vitiligo Study 2 (TRuE-V2): A Phase 3, Double-Blind, Randomized, Vehicle-Controlled, Efficacy and Safety Study of Ruxolitinib Cream Followed by an Extension Period in Participants With Vitiligo
Status: Completed, Estimated PCD: 2021-03-15
Clinical trial
A Prospective, Vehicle Controlled, Double Blind, Multicenter, Randomized, Phase II Study of B244 Delivered as a Topical Spray to Determine Safety and Efficacy in Subjects With Mild to Moderate Atopic Dermatitis
Status: Completed, Estimated PCD: 2019-02-27
Clinical trial
A Prospective, Controlled, Double Blind, Multi-Center, Randomized, 3 Arm, Phase 1b/2a Study to Assess the Safety, Tolerability, and Preliminary Efficacy of B244 Delivered as an Intranasal Spray in Healthy Volunteers and Subjects With Seasonal Allergic Rhinitis
Status: Completed, Estimated PCD: 2018-12-21
Clinical trial
A Phase 2, Multi-center, Double-blind, Randomized, Vehicle-controlled, Ascending Dose Study Assessing Tolerability, Safety, and Efficacy of Topical NVN1000 in Subjects With External Genital Warts and Perianal Warts
Status: Completed, Estimated PCD: 2016-10-01
Clinical trial
A Multi-Center, Double-Masked, Vehicle-Controlled, Evaluation of the Safety of CSF-1 in Presbyopic Subjects
Status: Completed, Estimated PCD: 2022-12-01
Clinical trial
A Multicenter, Randomized, Double-Blinded, Vehicle-Controlled Study to Evaluate the Safety and Efficacy of 3 Concentrations of Topically Applied BBI-4000 (Sofpironium Bromide) Gel in Subjects With Axillary Hyperhidrosis
Status: Completed, Estimated PCD: 2017-09-19
Clinical trial
Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy, Safety, and Tolerability of 36 Weeks of Treatment With NLY01 in Early-stage Parkinson's Disease
Status: Active (not recruiting), Estimated PCD: 2023-03-01
Clinical trial
Topical Ruxolitinib Evaluation in Chronic Hand Eczema Study 1 (TRuE-CHE1): A Phase 3, Double-Blind, Randomized, 16-Week, Vehicle-Controlled, Efficacy and Safety Study of Ruxolitinib Cream Followed by an Open-Label Extension Period in Adults With Chronic Hand Eczema
Status: Withdrawn, Estimated PCD: 2024-04-25
Clinical trial
A Phase 3, Multicenter, Randomized, Double-Masked Clinical Trial to Assess the Efficacy and Safety of Clobetasol Propionate Ophthalmic Nanoemulsion 0.05% Compared to Placebo in the Treatment of Inflammation and Pain Associated With Cataract Surgery
Status: Completed, Estimated PCD: 2021-04-14
Clinical trial
Topical Ruxolitinib Evaluation in Chronic Hand Eczema Study 2 (TRuE-CHE2): A Phase 3, Double-Blind, Randomized, 16-Week, Vehicle Controlled, Efficacy and Safety Study of Ruxolitinib Cream Followed by an Open-Label Extension Period in Adults With Chronic Hand Eczema
Status: Withdrawn, Estimated PCD: 2024-04-25
Clinical trial
A Multicenter, Randomized, Double-masked and Placebo-controlled Study Evaluating the Efficacy and Safety of SI-614 Ophthalmic Solution in Patients With Dry Eye
Status: , Estimated PCD: 2014-11-01
Clinical trial
A Randomized, Double-blind, Vehicle-Controlled, Seamless and Adaptive-designed Phase II/III Study to Evaluate the Efficacy and Safety of Topical SHR0302 Ointment in Adult Patients With Mild-to-Moderate Atopic Dermatitis
Status: Active (not recruiting), Estimated PCD: 2023-09-08
Clinical trial
A Phase 3, 8-Week, Parallel Group, Double Blind, Vehicle-Controlled Study of the Safety and Efficacy of ARQ-151 Cream 0.3% Administered QD in Subjects With Chronic Plaque Psoriasis
Status: Completed, Estimated PCD: 2020-11-16
Clinical trial
Topical Ruxolitinib Evaluation in Vitiligo Study 1 (TRuE-V1): A Phase 3, Double-Blind, Randomized, Vehicle-Controlled, Efficacy and Safety Study of Ruxolitinib Cream Followed by an Extension Period in Participants With Vitiligo
Status: Completed, Estimated PCD: 2021-03-18
Clinical trial
A Single-Center Evaluation of the Relative Efficacy of EM-100 Compared to Zaditor® (Ketotifen Fumarate Ophthalmic Solution 0.035%) and Vehicle in the Treatment of Ocular Itching Associated With Allergic Conjunctivitis as Induced by the Conjunctival Allergen Challenge Model (Ora-CAC®)
Status: Completed, Estimated PCD: 2018-04-29
Clinical trial
A Phase 3 Study Evaluating the Safety and Efficacy of AR-15512, a Cold Thermoreceptor Modulator, for the Treatment of Dry Eye Disease (COMET-2)
Status: Completed, Estimated PCD: 2023-07-21
Clinical trial
A Phase 1/2a, Randomized, Double-Masked, Vehicle-Controlled Study Evaluating the Safety and Exploratory Activity of Two Concentrations of ALY688 Ophthalmic Solution in Subjects With Dry Eye Disease
Status: Completed, Estimated PCD: 2020-09-15
Clinical trial
Multi-Center, Double-Blind, Randomized, Vehicle-Controlled, Parallel-Group Study to Compare Perrigo's Mupirocin Cream to A Reference Manufacturer's Mupirocin Cream and to Compare Both Active Treatments to a Vehicle Control in the Treatment of Secondarily Infected Traumatic Skin Lesions
Status: Completed, Estimated PCD: 2021-06-01
Clinical trial
A Multi-Center, Randomized, Double Masked, Vehicle Controlled Clinical Study to Assess the Safety and Efficacy of BRM421 Ophthalmic Solution in Subjects With Dry Eye Using a Controlled Adverse Environment (CAE®) Model
Status: Recruiting, Estimated PCD: 2023-12-30
Clinical trial
A Phase 2, Randomized, Double-Blind, Vehicle-Controlled Study Evaluating the Safety, Efficacy and Pharmacokinetics of Single Dose EP-104IAR for 24 Weeks in Patients With Osteoarthritis of the Knee
Status: Completed, Estimated PCD: 2023-05-17
Clinical trial
A Phase II, Randomized, Double-Blind, Vehicle Controlled Study of the Efficacy, Safety, and Tolerability of B244 Topical Spray for the Treatment of Pruritus in Adults With a History of Atopic Dermatitis
Status: Completed, Estimated PCD: 2021-12-10
Clinical trial
A Two-Stage, Phase 1/2 Study to Evaluate the Safety, Tolerability and Pharmacodynamics of CBT-009 Eye Drop in Healthy Volunteers
Status: Completed, Estimated PCD: 2023-01-18
Clinical trial
A Phase 3, Multicenter, Double-Masked, Randomized, Vehicle-Controlled, Parallel-Group Study Evaluating the Safety and Efficacy of BID Dosing of AGN-190584 in Subjects With Presbyopia
Status: Completed, Estimated PCD: 2022-02-11
Clinical trial
A Multicenter, Randomized, Double Blind, Vehicle-Controlled Study to Evaluate the Safety and Effect on Sweat Production of 3 Concentrations of Topically Applied BBI-4000 in Subjects With Axillary Hyperhidrosis
Status: Completed, Estimated PCD: 2015-11-05
Clinical trial
A Multicenter, Vehicle-controlled, Randomized Study to Evaluate the Safety, Tolerability, Systemic Pharmacokinetics, and Pharmacodynamics of AXR-159 Ophthalmic Solution 3 mg/mL, 30 mg/mL, and 50 mg/mL in Patients With Dry Eye Disease (DED)
Status: Completed, Estimated PCD: 2018-12-28
Clinical trial
A Randomized, Multicenter, Double-Masked, Vehicle-Controlled Phase 2/3 Study to Evaluate the Safety and Efficacy of NEXAGON® (Lufepirsen Ophthalmic Gel) in Subjects With Persistent Corneal Epithelial Defects (NEXPEDE-1)
Status: Recruiting, Estimated PCD: 2024-10-01
Clinical trial
A Prospective, Vehicle Controlled, Double Blinded, Multicenter, Randomized, Phase II Study of B244 Delivered as a Topical Spray to Determine Safety and Efficacy in Subjects With Elevated Blood Pressure
Status: Completed, Estimated PCD: 2017-04-25
Clinical trial
A Phase 3, Multicenter, Randomized, Double-Masked Clinical Trial to Assess the Efficacy and Safety of Clobetasol Propionate Ophthalmic Nanoemulsion 0.05% Compared to Placebo in the Treatment of Inflammation and Pain Associated With Cataract Surgery
Status: Completed, Estimated PCD: 2021-05-19
Clinical trial
614/1121
Status: , Estimated PCD: 2012-07-01
Clinical trial
A Phase 3, Randomized, Double-Blind, Vehicle-Controlled Study to Evaluate the Efficacy and Safety of Maintenance Treatment and Flare Reduction With Crisaborole Ointment, 2%, Once Daily Over 52 Weeks in Pediatric and Adult Participants (Ages 3 Months and Older) With Mild-to-Moderate Atopic Dermatitis, Who Responded to Twice Daily Crisaborole Ointment, 2%, Treatment
Status: Completed, Estimated PCD: 2022-01-19
Clinical trial
A Double-Masked, Multi-Center, Randomized, Vehicle- Controlled, Phase II Trial of the Efficacy and Safety of BRM424 Ophthalmic Solution in Patients With Neurotrophic Keratitis (NK)
Status: Not yet recruiting, Estimated PCD: 2025-01-30
Clinical trial
A Prospective, Randomized, Vehicle-Controlled, Double-Blind, Phase 2 Study to Assess the Safety, Tolerability, and Efficacy of B244 Delivered as an Intranasal Spray for Preventive Treatment in Subjects With Episodic Migraine
Status: Completed, Estimated PCD: 2019-06-17
Clinical trial
A Phase 2, Randomized, Double-blind,Placebo Controlled, Parallel Group Study to Assess Efficacy, Safety, and Pharmacokinetics (PK) of QLM3003 Ointment in Participants With Mild or Moderate Atopic Dermatitis
Status: Not yet recruiting, Estimated PCD: 2024-10-01
Clinical trial
A Randomized, Double-Blind, Vehicle-Controlled Study of the Safety, Tolerability and Efficacy of BTX 1204 in Patients With Moderate Atopic Dermatitis
Status: Completed, Estimated PCD: 2020-01-27
Clinical trial
Randomized, Double-Blind, Placebo-Controlled, Parallel-Design, Multi-Site Study to Evaluate Therapeutic Equivalence of Estradiol Vaginal Cream, USP, 0.01% (Prasco LLC) to Estrace® Cream (Warner Chilcott) in Treatment of Vulvar and Vaginal Atrophy
Status: Completed, Estimated PCD: 2018-03-15
Clinical trial
A Multi-center, Double-blind, Randomized, Vehicle-controlled Study of Efficacy and Safety of Topical MOB015B in the Treatment of Mild to Moderate Distal Subungual Onychomycosis (DSO)
Status: Active (not recruiting), Estimated PCD: 2024-02-01
Clinical trial
A Randomized, Double-Blind, Vehicle-Controlled, Parallel Group Phase 2 Dose-Response Study to Determine Safety and Effectiveness of Two Concentrations of NFX-179 Gel in Subjects With Cutaneous Neurofibromas
Status: Completed, Estimated PCD: 2023-10-04
Clinical trial
A Multi-center, Double-blind, Vehicle-controlled Study to Evaluate the Clinical Effect of Daily Next Science™ Acne Gel (NAG) on Mild to Moderate Facial Acne
Status: Completed, Estimated PCD: 2015-09-01
Clinical trial
A Double-Blind, Vehicle-Controlled, Randomized Withdrawal and Treatment Extension Study to Assess the Long-Term Efficacy and Safety of Ruxolitinib Cream in Participants With Vitiligo
Status: Completed, Estimated PCD: 2022-11-14
Clinical trial
A Pivotal, Double-Masked, Randomized, 2-stage, Multicenter Study of the Efficacy and Safety of OCS-01 Eye Drops in Subjects With Diabetic Macular Edema
Status: Active (not recruiting), Estimated PCD: 2025-06-30
Clinical trial
A Phase 2a, Multicenter, Randomized, Double-blind, Vehicle-controlled, Parallel-group Study to Determine the Safety, Tolerability, Pharmacokinetics and Efficacy of ATI-1777 in Adult Patients With Moderate or Severe Atopic Dermatitis
Status: Completed, Estimated PCD: 2021-04-08
Clinical trial
A Double-Masked Comparison of Apraclonidine Hydrochloride Ophthalmic Solution to Vehicle for the Reduction of Ocular Redness
Status: Not yet recruiting, Estimated PCD: 2024-12-01
Clinical trial
Phase 2 Multicenter, Double-blind, Randomized, Parallel-Group, Vehicle-Controlled Study to Evaluate the Efficacy, Safety, and Local Tolerability of G001 in Patients With Osteoarthritis (OA) of the Knee
Status: Completed, Estimated PCD: 2023-01-04
Clinical trial
Study of Efficacy, Safety and Tolerability of Crisaborole and PF-07038124 With and Without NBUVB in Vitiligo: A Phase 2A Randomized, Double-Blind, Vehicle-Controlled Clinical Trial
Status: Active (not recruiting), Estimated PCD: 2024-06-01
Clinical trial
A Phase 3, Multicenter, Double-Masked, Randomized, Vehicle-Controlled Study Evaluating the Safety and Efficacy of Pilocarpine HCl in Participants With Presbyopia
Status: Not yet recruiting, Estimated PCD: 2025-11-01
Clinical trial
A Multi-Center, Double-Masked Phase 3 Evaluation of the Safety and Efficacy of LNZ101 for the Treatment of Presbyopia
Status: Completed, Estimated PCD: 2023-12-14
Clinical trial
Effectiveness and Safety Comparison Between Moisturizers Containing Low Molecular Weight Hyaluronic Acid, High Molecular Weight Hyaluronic Acid, and Vehicle on Skin Hydration in the Elderly With Xerotic Skin
Status: Completed, Estimated PCD: 2023-09-30
Clinical trial
A Phase 3, Multicenter, Randomized, Double-Masked and Vehicle-Controlled Study Evaluating the Efficacy and Safety of Tanfanercept (HL036) Ophthalmic Solution 0.25% and 1.0% Compared to Vehicle in Participants With Dry Eye Disease (VELOS-4)
Status: , Estimated PCD: 2025-08-01
Clinical trial
A Randomized, Intraindividual, Phase 4 Study to Evaluate the Short-Term Efficacy of Triamcinolone Acetonide (Aristocort® C) in Subjects With Atopic Dermatitis
Status: Recruiting, Estimated PCD: 2024-04-30
Clinical trial
The Effect of Topical Agents With Various Antioxidant Containts on Photodamage Skin Induced by Ultraviolet B Radiation
Status: Active (not recruiting), Estimated PCD: 2023-07-31
Clinical trial
A Phase III, Randomized, Double-masked, Placebo-controlled, Parallel-group, Multicenter Study of the Safety and Efficacy of OT-101 (Atropine Sulfate 0.01%) in Treating the Progression of Myopia in Pediatric Subjects
Status: Active (not recruiting), Estimated PCD: 2027-03-01
Clinical trial
Multicenter, Double-Masked, Randomized, Safety and Efficacy Study of BRIMOCHOL™ PF and Carbachol PF Topical Ophthalmic Solution With Emmetropic Phakic and Pseudophakic Presbyopia
Status: Recruiting, Estimated PCD: 2024-12-31
Clinical trial
Pilot Studies Evaluating Use of Topical Imipramine and Amitriptyline in Reducing Ultraviolet B Light-Induced Redness in Patients With Rosacea
Status: Recruiting, Estimated PCD: 2028-12-01
Clinical trial
A Double-Masked, Randomized, Single-Center Study Evaluating the Effect of 0.30% Ketorolac/0.80% HPMC, 0.80% HPMC and Vehicle on Symptoms of Dry Eye After Exposure to the Controlled Adverse Environment (CAE)
Status: Withdrawn, Estimated PCD: 2009-06-15
Clinical trial
A Long-Term Safety Study Evaluating the Safety and Systemic Exposure of AR-15512, a Cold Thermoreceptor Modulator, for the Treatment of Dry Eye Disease (COMET-4)
Status: Completed, Estimated PCD: 2024-02-28
Clinical trial
Topical Androgen Receptor Inhibitor for Steroid-related Acne Vulgaris in Transgender Male Patients Receiving Masculinizing Hormone Therapy
Status: Recruiting, Estimated PCD: 2025-12-01
Clinical trial
Topical 5% Tranexamic Acid as a Treatment for Postinflammatory Hyperpigmentation Due to Acne Vulgaris
Status: Withdrawn, Estimated PCD: 2022-01-09
Clinical trial
A Randomized, Double-Blind, Vehicle-Controlled Study to Evaluate the Mechanism of Action of Ruxolitinib Cream for Vitiligo
Status: Completed, Estimated PCD: 2022-11-17
Clinical trial
Phase 2, Multicenter, Randomized, Double-Masked, Vehicle-Controlled Study of INV-102 Ophthalmic Solution in Adult Subjects With Moderate to Severe Dry Eye Disease
Status: Recruiting, Estimated PCD: 2024-08-01
Clinical trial
Examining the Therapeutic Potential of Botulinum Toxin Type A in the Treatment of Keloids
Status: Active (not recruiting), Estimated PCD: 2032-01-01